Abstract
The development of the current generation of antipsychotics has depended on animal, biochemical and pharmacological models of the action of drugs discovered serentipidously. They have focused on the dopamine hypothesis of schizophrenia. More recent studies of the structural abnormalities in schizophrenia, coupled with an understanding of the genetics and developmental biology of brain development, point to a new generation of novel medicines and therapies for patients with this disorder.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
